1. Treatment options for HUS secondary to Escherichia coli O157:H7
Martin Bitzan 
Kidney International 
Volume 75, Pages S62-S66 (February 2009)
DOI: /ki
Copyright © 2009 International Society of Nephrology Terms and Conditions

2. Figure 1
Clinical spectrum and evolution of infections by Shiga toxin-producing Escherichia coli. Arrow thickness indicates the risk or likelihood of that particular outcome.
Kidney International  , S62-S66DOI: ( /ki )
Copyright © 2009 International Society of Nephrology Terms and Conditions

3. Figure 2
Schematic diagram depicting the pathogenesis of Shiga toxin-producing Escherichia coli disease and putative interventions. LPS (lipopolysaccharide), Stx (Shiga toxin), STmAb (Stx-neutralizing monoclonal antibody), SAPK (stress-activated protein kinase [p38, JNK]). The numbers refer to therapeutic categories (see text).
Kidney International  , S62-S66DOI: ( /ki )
Copyright © 2009 International Society of Nephrology Terms and Conditions